The Journal of Obstetrics and Gynecology of India (May–June 2016) 66(3):188–191 DOI 10.1007/s13224-015-0737-2
CASE REPORT
Effectiveness of Recombinant Activated Factor VII (rFVII a) for Controlling Intractable Postpartum Bleeding in a case of Dengue Hemorrhagic Fever Arun Agarwal1,2 • Rakhi Jain1 • Samiksha Sharma1 Mala Airun1 • Bhavna Bharti1
•
Received: 1 April 2015 / Accepted: 1 July 2015 / Published online: 20 October 2015 Federation of Obstetric & Gynecological Societies of India 2015
About the Author Dr. Arun Agarwal completed his MD in 1989 from SMS Medical College, Jaipur. He is a practicing senior consultant in Internal Medicine with interest in sepsis and critical illness. He is a life member of Association of Physicians of India, Indian society of critical care medicine, Cardiological society of India, and RSSDI. He had been associated with Bhagwan Mahaveer Cancer Hospital & Research centre and Fortis Escorts Hospital, Jaipur and has almost 25 years of clinical experience. He is presently at Narayana Multispeciality Hospital, Jaipur as a senior consultant and Head, Department of Internal medicine. He has been a speaker, chaired sessions in various CME conferences, and was a speaker at the IFI Asia forum 2013 held at Chengdu(China). He is member of various hospital committees including infection control committee, Blood bank and Transfusion committee, ethical committee, and Authorization committee for organ transplant. He is also a faculty for diploma in Emergency medicine course. He is also member of a committee for making medical curriculum in Hindi for Atal Bihari Valpeye Hindi University, Bhopal.
Introduction Role of recombinant activated factor VII (rFVIIa) in controlling acute life-threatening bleeding has been reported in patients with hemophilia, Glanzmann’s thrombasthenia, liver failure, and dengue hemorrhagic fever (DHF), and in those who undergo cardiac surgery or neurosurgery. Most of these cases have been successfully treated with rFVIIa
& Arun Agarwal [email protected] 1
Departments of Internal Medicine, Obstetrics and Gynaecology, and Laboratory Medicine, Narayana Multispeciality Hospital, Sector 28, Kumbha Marg, Pratap Nagar, Jaipur, India
2
A-235, Shivanand Marg, Malviya Nagar, Jaipur, Rajasthan 302017, India
[1, 2]. The approach to treatment of postpartum hemorrhage (PPH) depends on the cause and the mode of delivery (vaginal or a cesarean delivery). Avoidance of laparotomy and/or hysterectomy should be the goal. Whatever may be the mode of delivery, there are potentially effective actions and interventions for management of PPH. We report a case of term pregnancy with DHF who developed massive PPH after normal delivery and was successfully managed with rFVIIa.
Case Presentation Ms. R.J, aged 25 years, was admitted on 18.12.2014 with 9 months gestation and mild labor pains since one day. A week before, she had fever with body ache for 2–3 days and was diagnosed to have primary dengue fever (DENF) on 12.12.2014. She tested positive for IgM antibodies to
123
The Journal of Obstetrics and Gynecology of India (May–June 2016) 66(3):188–191
dengue virus. She was treated on an OPD basis and her CBC (baseline and during hospitalization) and other blood tests are mentioned in Tables 1 and 2, respectively. On admission she had 38 weeks pregnancy uterus was contracting, with head at brim and fetal heart sounds were regular. Per vaginally os was 1 to 2 cm dilated, cervix was 50 % effaced, membranes present and vertex was at -3 station. Outlet forceps-aided vaginal delivery was done on 19.12.2017 at 7.34 pm and she delivered a healthy baby weighing 3.74 kg. She developed mild PPH post delivery which was managed with oxytocin infusion, carboprost 125 mcg intra-muscularly, and tablet Misoprostol 800 mcg per rectum. After about 2 h, she developed per vaginal bleeding without any clots. Uterine massage was done though it was well contracted. However, in view of significant bleeding, she was shifted to the operation theater for uterine packing and her coagulation profile was sent. Her baseline PT-INR on 20.12.14 at 11.45 PM was 1.35 (Table 1). Her D-dimer and serum fibrinogen levels are mentioned in Table 2. Uterine packing was done with roller gauze under general anesthesia as she was hemodynamically unstable and developed hypotension with cold clammy skin. However, she continued to have moderate per vaginal bleeding and also oozing from episiotomy wound. Post procedure, she was shifted to MICU for further management on mechanical ventilator. In the meantime, uterine artery embolization vs hysterectomy was discussed with cardiologist and it was planned to proceed with uterine artery embolization. Angiography of bilateral common and internal iliac artery was performed, but no active bleeder was found. An opinion was then sought from an internist and in view of coagulopathy and history of recent DENF, dengue hemorrhagic fever-dengue shock syndrome was suspected. Since she had intractable bleeding and coagulopathy, she was considered for recombinant activated factor VII (Novo 7) in a dose of 6 mg IV (90–100 mcg/kg) slow intravenous injection over 3–5 min. In all, she received 10 units of packed red blood cells, 11 units of random donar platelets, 1 unit SDP, 10 units fresh frozen plasma, and 9 units of cryoprecipitate to maintain hemoglobin level around 8 gm %, platelet count [50,000/cmm, PT-INR \ 1.5, and serum fibrinogen level [200 mg/dl. Within minutes of giving her Novo 7 injection, bleeding was controlled except for some mild oozing locally. She was given an additional dose of 4 mg of Novo 7 intravenously after 2 h. With 2 doses of Novo 7, her per vaginal bleeding completely stopped. During this period, she also developed hypotension, acute renal failure (non-oliguric), hepatitis, and features of capillary leak syndrome (gall bladder wall edema, bilateral mild pleural effusion, and trace ascites). Figure 1 shows her X-ray chest on 20.12.2014 which was normal, and Fig. 2 depicts her X-ray chest on 22.12.2014 showing bilateral mild pleural effusion
123
Effectiveness of Recombinant Activated Factor VII (rFVII a)…
due to capillary leak syndrome. These were all attributed to DHF. In MICU, she was managed with vasopressors, antibiotics (cefoperozone ? sulbactum and moxifloxacin initially and later imipinem ? cilastin and teicoplanin), and blood products as mentioned above. For acute renal failure, she did not require any renal support and it was managed medically with fluid and electrolytes, diuretics, and supportive treatment. She was weaned off and extubated on 20.12.14. Uterine pack was removed on 21.12.2014. She was discharged on 31.12.2014.
Discussion Dengue is a mosquito-borne disease caused by any of the four dengue viruses (DENV-1, -2, -3, and -4). However, some patients with DENF develop a severe and at times fatal form of the disease called DHF. This happens at a time when fever begins to subside (usually 3–7 days after symptom onset) and patient develops warning signs of severe disease. A WHO definition of dengue hemorrhagic fever states that for diagnosis, all four of the following criteria must be fulfilled: fever, hemorrhagic tendency, thrombocytopenia, and evidence of plasma leak. All the above along with a weak rapid pulse and a narrow pulse pressure or hypotension, cold clammy skin, and restlessness constitute the dengue shock syndrome (DSS) [3]. Patients with dengue can rapidly progress to DSS, which, if not treated correctly, can lead to severe complications and death. Literature search reveals an increased incidence of preterm deliveries, low birth weight, pre-eclampsia, and cesarean sections in DENF. Vertical transmission has also been noted [4–6]. The gestational age at presentation of dengue fever also appears to be significant with early or late pregnancy having a poor prognosis; [7]. In case of infection close to term, there is a risk of hemorrhage for both the mother and the newborn. The most common hemorrhagic manifestations are mild and include a positive tourniquet test, skin hemorrhages (petechiae, hematomas), epistaxis (nose bleed), gingival bleeding (gum bleed), and microscopic hematuria. More serious types of hemorrhage include vaginal bleeding, hematemesis, melena, and intracranial bleeding. Our patient developed fever few days before delivery and was diagnosed with primary DENF. A week later, she came with mild labor pains and developed severe fatal form of the disease DHFDSS following vaginal delivery. Chitra et al. analyzed pregnant women with dengue fever who were admitted in the obstetric ward and determined the adverse effects of fever on pregnancy and the fetal outcome. During a period of 18 months from 2009 to 2010, a total of 2738 deliveries occurred and 14 cases of pregnant women with dengue fever were identified. Among them, the DHF was seen in three individuals. However,
189
Agarwal et al.
The Journal of Obstetrics and Gynecology of India (May–June 2016) 66(3):188–191
Table 1 Patient’s hematology and biochemistry parameters Date
Hb
TLC
3
10 /cmm
gm/dl AM
Platelets count
3
PM
AM
10 /cmm PM
AM
AST
ALT
Creatinine
IU/L
IU/L
Mg/dl
PM
12.12.14
11.5
6.86
105
13.12.14
11.3
5.62
92
14.12.14 18.12.14
11.3 12.6
5.4 6.46
100 132
20.12.14
6.8
5.9
18
13
77
39
21.12.14
7.9
7.2
17.37
15
86
54
22.12.14
9.6
14.23
23.12.14
10.9
24.12.14
11.3
25.12.14 26.12.14
PT-INR
AM
PM
31
27 1.26
1.35/2.1
1.6
1445
743
3.47
1.5
1.7
58
741
786
4.38
10.67
49
531
659
4.68
9.97
53
11.2
9.05
43
9.6
9.27
42
2.57
27.12.14
9.1
8.67
65
1.91
28.12.14
8.6
8.97
96
1.53
29.12.14
9
9.1
150
1.28
31.12.14
9.6
10.32
249
1.4
4.91 69
24.01.15
36
174
3.64
39
Table 2 Other investigations including coagulation profile Date
Test
Report
Normal Range
D-Dimer
0.9 mg/L
\0.3
Plasma Fibrinogen
150 mg/dl
200–400
21.12.14
Plasma Fibrinogen USG abdomen
225 mg/dl Mild bilateral pleural effusion, GB wall edema, trace ascites.
200–400
22.12.14
Dengue IgG ab
Negative
XRC
Bilateral mild pleural effusion
24.12.14
Urine C/S
Sterile
24.12.14
Blood C/S
Sterile
25.12.14
SES Sepsis
Negative for Gram-positive organism, Gram-negative organism, and Fungi.
28.12.14
TSH Urine Routine Exam
1.58 mIU/L Albumin ??; Pus cells 6-8/hpf; RBC Numerous; Granular casts ?
29.12.14
Urine C/S
Sterile
20.12.14
there was no case of DSS. DHF was diagnosed when they had DENF with ultrasound evidence of pleural effusion, ascites, and gall bladder thickening [7]. Ismail et al. state a maternal mortality of 2.6 % [8]. Fatality rates among patients with DSS can be 10 % or higher. Maqsud et al. from Pakistan reported a study of 18 pregnant patients with DENF presenting at different gestational ages between 34 and 41 weeks of gestation. They report bleeding manifestations in 10 patients including PPH in 5 of them, out of which 2 patients required hysterectomy [9].
190
0.46–4.68
Massive obstetric bleeding may lead to fatal outcome in about 10 % of cases. Bleeding is treated according to the underlying cause, concomitant with rapid transfusion of blood and coagulation factors. Conventionally, bleeding is usually controlled by surgical means such as uterine artery ligation, internal iliac artery ligation, B-Lynch suture, hysterectomy, or intra-arterial embolization. However, there will still be some cases who fail all these attempts, resulting in sudden fatality of the new mothers. Recently, there have been reports of using rFVIIa for obstetric hemorrhage [1].
123
The Journal of Obstetrics and Gynecology of India (May–June 2016) 66(3):188–191
Effectiveness of Recombinant Activated Factor VII (rFVII a)…
intractable hemorrhage and coagulopathy with an understanding that cost is the major constraint.
Conclusion
Fig. 1 Normal XR Chest dated 20.12.2014
Any fever should be evaluated for possible cause, especially in early as well as late pregnancy. The present case report shows that massive postpartum hemorrhage could not be controlled with standard therapy short of hysterectomy, but was controlled successfully by rFVIIa. It highlights the role of rFVIIa not only in obstetric emergencies but also in DHF. The administration of rFVIIa is indicated only after all routine procedures in controlling massive hemorrhage have failed. It results in quick arrest of bleeding and may be life saving and prevent unwarranted hysterectomies in young mothers. However, due to high cost, it should be really the last resort after all conventional procedures have failed. Acknowledgments The authors acknowledge the support of Dr. Devendra Shrimal (cardiology), Dr Vivek Bhargava (critical care), Anaesthesia/OT/Labour room team, and Dr Pallavi Maheshwari (Blood bank) for their help and support in the management of this patient. Conflict of interest
None.
References
Fig. 2 XR Chest dated 22.12.2014 showing bilateral mild pleural effusion
Most cases used rFVIIa after all procedures failed to control bleeding. In our case also, uterine arterial embolization was planned but no active bleeder could be identified on angiography, the underlying etiology being DHF. When all procedures failed to control bleeding, we considered her for rFVIIa. Intractable hemorrhage stopped after treatment with rFVIIa. Thus, rFVIIa may be given a trial as an adjunctive therapy for control of massive hemorrhage before considering patient for surgical intervention. We conclude that rFVIIa is a promising therapy when standard therapy fails; the drug is very expensive and may increase the risk of thromboembolism events. It should be reserved for cases of
123
1. Jirapinyo M, Manonai J, Herabutya Y. Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review. J Med Assoc Thai. 2007;90(5):977–81. 2. Chuansumrita A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005;16: 1549–55. 3. World Health organization guidelines for treatment of dengue fever/Dengue hemorrhagic fever (DF/DHF). Grading the severity of dengue infection. 1999;2:3–5. 4. Maroun S, Marliere R, Barcellus R, et al. Case report: vertical dengue infection. Jornal de Pediatria. 2008;84:556–9. 5. Chotigeat U, Kalayanrooj S, Nisalak A. Vertical transmission of dengue infection in Thai infants: two case reports. J Med Assoc Thai. 2003;86:S628–32. 6. Singh N, Sharma KA, Dadhwal V. A successful management of dengue fever in pregnancy: report of two cases. Indian J med Microbiol. 2008;26(4):377–80. 7. Chitra TV, Panicker S. Maternal and fetal outcome of dengue fever in pregnancy. J Vector Borne Dis. 2011;48(4):210–3. 8. Ismail NA, Kampan N, Mahdy Z. Dengue in pregnancy. Southeast Asian J Trop Med Public Health. 2006;37:681–3. 9. Maqsud M, Zafar F, Naz U. Dilemma of dengue fever in pregnancy a clinical management experience at a tertiary care hospital. Pak J Med Health Sci. 2012;6(2):317.
191
CASE REPORT
Effectiveness of Recombinant Activated Factor VII (rFVII a) for Controlling Intractable Postpartum Bleeding in a case of Dengue Hemorrhagic Fever Arun Agarwal1,2 • Rakhi Jain1 • Samiksha Sharma1 Mala Airun1 • Bhavna Bharti1
•
Received: 1 April 2015 / Accepted: 1 July 2015 / Published online: 20 October 2015 Federation of Obstetric & Gynecological Societies of India 2015
About the Author Dr. Arun Agarwal completed his MD in 1989 from SMS Medical College, Jaipur. He is a practicing senior consultant in Internal Medicine with interest in sepsis and critical illness. He is a life member of Association of Physicians of India, Indian society of critical care medicine, Cardiological society of India, and RSSDI. He had been associated with Bhagwan Mahaveer Cancer Hospital & Research centre and Fortis Escorts Hospital, Jaipur and has almost 25 years of clinical experience. He is presently at Narayana Multispeciality Hospital, Jaipur as a senior consultant and Head, Department of Internal medicine. He has been a speaker, chaired sessions in various CME conferences, and was a speaker at the IFI Asia forum 2013 held at Chengdu(China). He is member of various hospital committees including infection control committee, Blood bank and Transfusion committee, ethical committee, and Authorization committee for organ transplant. He is also a faculty for diploma in Emergency medicine course. He is also member of a committee for making medical curriculum in Hindi for Atal Bihari Valpeye Hindi University, Bhopal.
Introduction Role of recombinant activated factor VII (rFVIIa) in controlling acute life-threatening bleeding has been reported in patients with hemophilia, Glanzmann’s thrombasthenia, liver failure, and dengue hemorrhagic fever (DHF), and in those who undergo cardiac surgery or neurosurgery. Most of these cases have been successfully treated with rFVIIa
& Arun Agarwal [email protected] 1
Departments of Internal Medicine, Obstetrics and Gynaecology, and Laboratory Medicine, Narayana Multispeciality Hospital, Sector 28, Kumbha Marg, Pratap Nagar, Jaipur, India
2
A-235, Shivanand Marg, Malviya Nagar, Jaipur, Rajasthan 302017, India
[1, 2]. The approach to treatment of postpartum hemorrhage (PPH) depends on the cause and the mode of delivery (vaginal or a cesarean delivery). Avoidance of laparotomy and/or hysterectomy should be the goal. Whatever may be the mode of delivery, there are potentially effective actions and interventions for management of PPH. We report a case of term pregnancy with DHF who developed massive PPH after normal delivery and was successfully managed with rFVIIa.
Case Presentation Ms. R.J, aged 25 years, was admitted on 18.12.2014 with 9 months gestation and mild labor pains since one day. A week before, she had fever with body ache for 2–3 days and was diagnosed to have primary dengue fever (DENF) on 12.12.2014. She tested positive for IgM antibodies to
123
The Journal of Obstetrics and Gynecology of India (May–June 2016) 66(3):188–191
dengue virus. She was treated on an OPD basis and her CBC (baseline and during hospitalization) and other blood tests are mentioned in Tables 1 and 2, respectively. On admission she had 38 weeks pregnancy uterus was contracting, with head at brim and fetal heart sounds were regular. Per vaginally os was 1 to 2 cm dilated, cervix was 50 % effaced, membranes present and vertex was at -3 station. Outlet forceps-aided vaginal delivery was done on 19.12.2017 at 7.34 pm and she delivered a healthy baby weighing 3.74 kg. She developed mild PPH post delivery which was managed with oxytocin infusion, carboprost 125 mcg intra-muscularly, and tablet Misoprostol 800 mcg per rectum. After about 2 h, she developed per vaginal bleeding without any clots. Uterine massage was done though it was well contracted. However, in view of significant bleeding, she was shifted to the operation theater for uterine packing and her coagulation profile was sent. Her baseline PT-INR on 20.12.14 at 11.45 PM was 1.35 (Table 1). Her D-dimer and serum fibrinogen levels are mentioned in Table 2. Uterine packing was done with roller gauze under general anesthesia as she was hemodynamically unstable and developed hypotension with cold clammy skin. However, she continued to have moderate per vaginal bleeding and also oozing from episiotomy wound. Post procedure, she was shifted to MICU for further management on mechanical ventilator. In the meantime, uterine artery embolization vs hysterectomy was discussed with cardiologist and it was planned to proceed with uterine artery embolization. Angiography of bilateral common and internal iliac artery was performed, but no active bleeder was found. An opinion was then sought from an internist and in view of coagulopathy and history of recent DENF, dengue hemorrhagic fever-dengue shock syndrome was suspected. Since she had intractable bleeding and coagulopathy, she was considered for recombinant activated factor VII (Novo 7) in a dose of 6 mg IV (90–100 mcg/kg) slow intravenous injection over 3–5 min. In all, she received 10 units of packed red blood cells, 11 units of random donar platelets, 1 unit SDP, 10 units fresh frozen plasma, and 9 units of cryoprecipitate to maintain hemoglobin level around 8 gm %, platelet count [50,000/cmm, PT-INR \ 1.5, and serum fibrinogen level [200 mg/dl. Within minutes of giving her Novo 7 injection, bleeding was controlled except for some mild oozing locally. She was given an additional dose of 4 mg of Novo 7 intravenously after 2 h. With 2 doses of Novo 7, her per vaginal bleeding completely stopped. During this period, she also developed hypotension, acute renal failure (non-oliguric), hepatitis, and features of capillary leak syndrome (gall bladder wall edema, bilateral mild pleural effusion, and trace ascites). Figure 1 shows her X-ray chest on 20.12.2014 which was normal, and Fig. 2 depicts her X-ray chest on 22.12.2014 showing bilateral mild pleural effusion
123
Effectiveness of Recombinant Activated Factor VII (rFVII a)…
due to capillary leak syndrome. These were all attributed to DHF. In MICU, she was managed with vasopressors, antibiotics (cefoperozone ? sulbactum and moxifloxacin initially and later imipinem ? cilastin and teicoplanin), and blood products as mentioned above. For acute renal failure, she did not require any renal support and it was managed medically with fluid and electrolytes, diuretics, and supportive treatment. She was weaned off and extubated on 20.12.14. Uterine pack was removed on 21.12.2014. She was discharged on 31.12.2014.
Discussion Dengue is a mosquito-borne disease caused by any of the four dengue viruses (DENV-1, -2, -3, and -4). However, some patients with DENF develop a severe and at times fatal form of the disease called DHF. This happens at a time when fever begins to subside (usually 3–7 days after symptom onset) and patient develops warning signs of severe disease. A WHO definition of dengue hemorrhagic fever states that for diagnosis, all four of the following criteria must be fulfilled: fever, hemorrhagic tendency, thrombocytopenia, and evidence of plasma leak. All the above along with a weak rapid pulse and a narrow pulse pressure or hypotension, cold clammy skin, and restlessness constitute the dengue shock syndrome (DSS) [3]. Patients with dengue can rapidly progress to DSS, which, if not treated correctly, can lead to severe complications and death. Literature search reveals an increased incidence of preterm deliveries, low birth weight, pre-eclampsia, and cesarean sections in DENF. Vertical transmission has also been noted [4–6]. The gestational age at presentation of dengue fever also appears to be significant with early or late pregnancy having a poor prognosis; [7]. In case of infection close to term, there is a risk of hemorrhage for both the mother and the newborn. The most common hemorrhagic manifestations are mild and include a positive tourniquet test, skin hemorrhages (petechiae, hematomas), epistaxis (nose bleed), gingival bleeding (gum bleed), and microscopic hematuria. More serious types of hemorrhage include vaginal bleeding, hematemesis, melena, and intracranial bleeding. Our patient developed fever few days before delivery and was diagnosed with primary DENF. A week later, she came with mild labor pains and developed severe fatal form of the disease DHFDSS following vaginal delivery. Chitra et al. analyzed pregnant women with dengue fever who were admitted in the obstetric ward and determined the adverse effects of fever on pregnancy and the fetal outcome. During a period of 18 months from 2009 to 2010, a total of 2738 deliveries occurred and 14 cases of pregnant women with dengue fever were identified. Among them, the DHF was seen in three individuals. However,
189
Agarwal et al.
The Journal of Obstetrics and Gynecology of India (May–June 2016) 66(3):188–191
Table 1 Patient’s hematology and biochemistry parameters Date
Hb
TLC
3
10 /cmm
gm/dl AM
Platelets count
3
PM
AM
10 /cmm PM
AM
AST
ALT
Creatinine
IU/L
IU/L
Mg/dl
PM
12.12.14
11.5
6.86
105
13.12.14
11.3
5.62
92
14.12.14 18.12.14
11.3 12.6
5.4 6.46
100 132
20.12.14
6.8
5.9
18
13
77
39
21.12.14
7.9
7.2
17.37
15
86
54
22.12.14
9.6
14.23
23.12.14
10.9
24.12.14
11.3
25.12.14 26.12.14
PT-INR
AM
PM
31
27 1.26
1.35/2.1
1.6
1445
743
3.47
1.5
1.7
58
741
786
4.38
10.67
49
531
659
4.68
9.97
53
11.2
9.05
43
9.6
9.27
42
2.57
27.12.14
9.1
8.67
65
1.91
28.12.14
8.6
8.97
96
1.53
29.12.14
9
9.1
150
1.28
31.12.14
9.6
10.32
249
1.4
4.91 69
24.01.15
36
174
3.64
39
Table 2 Other investigations including coagulation profile Date
Test
Report
Normal Range
D-Dimer
0.9 mg/L
\0.3
Plasma Fibrinogen
150 mg/dl
200–400
21.12.14
Plasma Fibrinogen USG abdomen
225 mg/dl Mild bilateral pleural effusion, GB wall edema, trace ascites.
200–400
22.12.14
Dengue IgG ab
Negative
XRC
Bilateral mild pleural effusion
24.12.14
Urine C/S
Sterile
24.12.14
Blood C/S
Sterile
25.12.14
SES Sepsis
Negative for Gram-positive organism, Gram-negative organism, and Fungi.
28.12.14
TSH Urine Routine Exam
1.58 mIU/L Albumin ??; Pus cells 6-8/hpf; RBC Numerous; Granular casts ?
29.12.14
Urine C/S
Sterile
20.12.14
there was no case of DSS. DHF was diagnosed when they had DENF with ultrasound evidence of pleural effusion, ascites, and gall bladder thickening [7]. Ismail et al. state a maternal mortality of 2.6 % [8]. Fatality rates among patients with DSS can be 10 % or higher. Maqsud et al. from Pakistan reported a study of 18 pregnant patients with DENF presenting at different gestational ages between 34 and 41 weeks of gestation. They report bleeding manifestations in 10 patients including PPH in 5 of them, out of which 2 patients required hysterectomy [9].
190
0.46–4.68
Massive obstetric bleeding may lead to fatal outcome in about 10 % of cases. Bleeding is treated according to the underlying cause, concomitant with rapid transfusion of blood and coagulation factors. Conventionally, bleeding is usually controlled by surgical means such as uterine artery ligation, internal iliac artery ligation, B-Lynch suture, hysterectomy, or intra-arterial embolization. However, there will still be some cases who fail all these attempts, resulting in sudden fatality of the new mothers. Recently, there have been reports of using rFVIIa for obstetric hemorrhage [1].
123
The Journal of Obstetrics and Gynecology of India (May–June 2016) 66(3):188–191
Effectiveness of Recombinant Activated Factor VII (rFVII a)…
intractable hemorrhage and coagulopathy with an understanding that cost is the major constraint.
Conclusion
Fig. 1 Normal XR Chest dated 20.12.2014
Any fever should be evaluated for possible cause, especially in early as well as late pregnancy. The present case report shows that massive postpartum hemorrhage could not be controlled with standard therapy short of hysterectomy, but was controlled successfully by rFVIIa. It highlights the role of rFVIIa not only in obstetric emergencies but also in DHF. The administration of rFVIIa is indicated only after all routine procedures in controlling massive hemorrhage have failed. It results in quick arrest of bleeding and may be life saving and prevent unwarranted hysterectomies in young mothers. However, due to high cost, it should be really the last resort after all conventional procedures have failed. Acknowledgments The authors acknowledge the support of Dr. Devendra Shrimal (cardiology), Dr Vivek Bhargava (critical care), Anaesthesia/OT/Labour room team, and Dr Pallavi Maheshwari (Blood bank) for their help and support in the management of this patient. Conflict of interest
None.
References
Fig. 2 XR Chest dated 22.12.2014 showing bilateral mild pleural effusion
Most cases used rFVIIa after all procedures failed to control bleeding. In our case also, uterine arterial embolization was planned but no active bleeder could be identified on angiography, the underlying etiology being DHF. When all procedures failed to control bleeding, we considered her for rFVIIa. Intractable hemorrhage stopped after treatment with rFVIIa. Thus, rFVIIa may be given a trial as an adjunctive therapy for control of massive hemorrhage before considering patient for surgical intervention. We conclude that rFVIIa is a promising therapy when standard therapy fails; the drug is very expensive and may increase the risk of thromboembolism events. It should be reserved for cases of
123
1. Jirapinyo M, Manonai J, Herabutya Y. Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review. J Med Assoc Thai. 2007;90(5):977–81. 2. Chuansumrita A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005;16: 1549–55. 3. World Health organization guidelines for treatment of dengue fever/Dengue hemorrhagic fever (DF/DHF). Grading the severity of dengue infection. 1999;2:3–5. 4. Maroun S, Marliere R, Barcellus R, et al. Case report: vertical dengue infection. Jornal de Pediatria. 2008;84:556–9. 5. Chotigeat U, Kalayanrooj S, Nisalak A. Vertical transmission of dengue infection in Thai infants: two case reports. J Med Assoc Thai. 2003;86:S628–32. 6. Singh N, Sharma KA, Dadhwal V. A successful management of dengue fever in pregnancy: report of two cases. Indian J med Microbiol. 2008;26(4):377–80. 7. Chitra TV, Panicker S. Maternal and fetal outcome of dengue fever in pregnancy. J Vector Borne Dis. 2011;48(4):210–3. 8. Ismail NA, Kampan N, Mahdy Z. Dengue in pregnancy. Southeast Asian J Trop Med Public Health. 2006;37:681–3. 9. Maqsud M, Zafar F, Naz U. Dilemma of dengue fever in pregnancy a clinical management experience at a tertiary care hospital. Pak J Med Health Sci. 2012;6(2):317.
191
